Christian S. Hinrichs, M.D.

Lasker Clinical Research Scholar

Experimental Transplantation and Immunology Branch

NCI/CCR

Building 10, Room 4B04
Bethesda, MD 20892

301-435-3027

hinrichs@mail.nih.gov

Research Topics

Cellular Therapy for Cancer

Dr. Hinrichs conducts basic and clinical research to discover and develop novel T cell therapies for the treatment of patients with cancer. This work includes a clinical trial of HPV-targeted tumor-infiltrating T cells for patients with HPV+ cancers, which has demonstrated that this treatment can mediate complete regression of cervical cancer in some patients. Dr. Hinrichs' laboratory also has discovered genes for T cell receptors that target HPV, and his group is testing new gene therapy treatments based on these receptors for patients with advanced HPV+ tumors.

Biography

Dr. Hinrichs received his B.A. and M.D. degrees from the combined 6-year program at the University of Missouri - Kansas City (UMKC). He completed a residency in general surgery at UMKC followed by a fellowship in surgical oncology at Roswell Park Cancer Institute. He then came to the Surgery Branch at the National Cancer Institute (NCI) as a surgical oncology fellow and studied tumor immunology in the laboratory of Dr. Nicholas P. Restifo. Subsequently he completed an internal medicine residency at George Washington University and a medical oncology fellowship with the Medical Oncology Branch, CCR. Dr. Hinrichs conducts translational research and clinical trials to develop T-cell therapies for cancers caused by human papillomaviruses.

Selected Publications

  1. Stevanović S, Pasetto A, Helman SR, Gartner JJ, Prickett TD, Howie B, Robins HS, Robbins PF, Klebanoff CA, Rosenberg SA, Hinrichs CS. Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer. Science. 2017;356(6334):200-205.

  2. Stevanović S, Draper LM, Langhan MM, Campbell TE, Kwong ML, Wunderlich JR, Dudley ME, Yang JC, Sherry RM, Kammula US, Restifo NP, Rosenberg SA, Hinrichs CS. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol. 2015;33(14):1543-50.

  3. Draper LM, Kwong ML, Gros A, Stevanović S, Tran E, Kerkar S, Raffeld M, Rosenberg SA, Hinrichs CS. Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6. Clin Cancer Res. 2015;21(19):4431-9.

  4. Hinrichs CS, Rosenberg SA. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev. 2014;257(1):56-71.

  5. Hinrichs CS, Restifo NP. Reassessing target antigens for adoptive T-cell therapy. Nat Biotechnol. 2013;31(11):999-1008.


This page was last updated on September 20th, 2017